Details of t-MN patient demographics, treatment, and outcome
| Patient . | Tx arm × no. of cycles . | Age (y) at study entry/sex . | IgVH mutation status . | CLL FISH . | CLL response . | Additional therapy . | Time to t-MN, mo . | Survival after t-MN, mo . | t-MN cytogenetics . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FC × 4 | 69/Male | Mutated | 13q− | CR | 59 | 17 | 46,XY,−6,add(7)(q22),del(20)(q11.2q13.1), +mar[4]/47,XY,add(9)(q13),add(10)(p11.2), +11[cp4]/46XY[12] | |
| 2 | FC × 6 | 57/Male | Mutated | 13q−, +12 | PR | 85 | 1 | Not tested | |
| 3 | FC × 6 | 47/Male | Mutated | Normal | PR | 72 | 6 | 46,XY,del(5)(q13q33),−7,t(7;10)(q35;q22), i(8)(q10),del(11)(q22q25),der(11)invdup(11) (25q13)dup(11)(q13q25),add(17)(p13), del(17)(q23q25),+mar[18]/46,XY[2] | |
| 4 | FC × 6 | 64/Female | Not tested | Not tested | CR | 25 | 13 | 45,XX,der(5)t(5;12)(q10;q11),del(7)(q32q34), −12,del(13)(q12)[16]/45,XX,der(5)t(5;12) (q10;q11), del(7)(q32q34),der(12)t(12;13) (q10;q21),13[8]/46,XX,−5,+8,del(13)(q12) [4]/46,XX[7] | |
| 5 | FR × 6 | 60/Female | Mutated | 13q− | PR | 39 | 7 | 44−48,XX,del(3)(p23),add(5)(q11.2),dic(21;?) (q22;?),+0−2mar[cp15]/46,XX[5] | |
| 6 | FC × 6 | 70/Female | Not tested | Not tested | PR | Alkylators | 72 | 7+ | 47−48,XX,−2,−8,add(11)(p15),+22,+2−4mar, inc[cp7]/46,XX[6] |
| 7 | FC × 2 | 68/Male | Mutated | 13q−; 17p− | PD | Etoposide; others | 65 | 9+ | 42,XY,−4,der(7)t(7;8)(p22;q13),−8,add(17) (p13),−20,−21[cp4]/46,XY[9] |
| 8 | FC × 6 | 80/Male | Mutated | Normal | CR | 40 | 20 | 45,XY,−7,del(12)(p11.2)[cp10]/47,XY,+8[2]/46, XY[8] | |
| 9 | FC × 6 | 51/Male | Mutated | 13q− | PR | 61 | 1+ | 45,XY,−7[17]/46,XY[3] | |
| 10 | F × 1 | 58/Male | Not mutated | 13q−; 11q− | Unknown | FR | 84 | 4 | 45,XY,t(3;8)(q23;p23.1),der(5)t(5;7)(q13;p13), −7,del(13)(q21.2q22)[20] |
| 11 | F × 6 | 45/Male | Not mutated | 14q; +12 | PR | FCR; NMSCT | 73 | 12+ | 47,XY,+add(12)(q13),t(14;19)(q32;13.3)[4]/46, XY[6] |
| 12 | F × 6 | 76/Female | Mutated | 13q− | PR | 8 | 30 | 46,XX,+1,der(1;15)(q10;p10)[6]/46,XX[24] | |
| 13 | F × 6 | 56/Male | Not mutated | 13q− | PR | Alkylators; other | 72 | 10+ | 47,XY,add(7)(q11.2),del(20)(q11.2q13.3), +21[18]/46,XY[2] |
| Patient . | Tx arm × no. of cycles . | Age (y) at study entry/sex . | IgVH mutation status . | CLL FISH . | CLL response . | Additional therapy . | Time to t-MN, mo . | Survival after t-MN, mo . | t-MN cytogenetics . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FC × 4 | 69/Male | Mutated | 13q− | CR | 59 | 17 | 46,XY,−6,add(7)(q22),del(20)(q11.2q13.1), +mar[4]/47,XY,add(9)(q13),add(10)(p11.2), +11[cp4]/46XY[12] | |
| 2 | FC × 6 | 57/Male | Mutated | 13q−, +12 | PR | 85 | 1 | Not tested | |
| 3 | FC × 6 | 47/Male | Mutated | Normal | PR | 72 | 6 | 46,XY,del(5)(q13q33),−7,t(7;10)(q35;q22), i(8)(q10),del(11)(q22q25),der(11)invdup(11) (25q13)dup(11)(q13q25),add(17)(p13), del(17)(q23q25),+mar[18]/46,XY[2] | |
| 4 | FC × 6 | 64/Female | Not tested | Not tested | CR | 25 | 13 | 45,XX,der(5)t(5;12)(q10;q11),del(7)(q32q34), −12,del(13)(q12)[16]/45,XX,der(5)t(5;12) (q10;q11), del(7)(q32q34),der(12)t(12;13) (q10;q21),13[8]/46,XX,−5,+8,del(13)(q12) [4]/46,XX[7] | |
| 5 | FR × 6 | 60/Female | Mutated | 13q− | PR | 39 | 7 | 44−48,XX,del(3)(p23),add(5)(q11.2),dic(21;?) (q22;?),+0−2mar[cp15]/46,XX[5] | |
| 6 | FC × 6 | 70/Female | Not tested | Not tested | PR | Alkylators | 72 | 7+ | 47−48,XX,−2,−8,add(11)(p15),+22,+2−4mar, inc[cp7]/46,XX[6] |
| 7 | FC × 2 | 68/Male | Mutated | 13q−; 17p− | PD | Etoposide; others | 65 | 9+ | 42,XY,−4,der(7)t(7;8)(p22;q13),−8,add(17) (p13),−20,−21[cp4]/46,XY[9] |
| 8 | FC × 6 | 80/Male | Mutated | Normal | CR | 40 | 20 | 45,XY,−7,del(12)(p11.2)[cp10]/47,XY,+8[2]/46, XY[8] | |
| 9 | FC × 6 | 51/Male | Mutated | 13q− | PR | 61 | 1+ | 45,XY,−7[17]/46,XY[3] | |
| 10 | F × 1 | 58/Male | Not mutated | 13q−; 11q− | Unknown | FR | 84 | 4 | 45,XY,t(3;8)(q23;p23.1),der(5)t(5;7)(q13;p13), −7,del(13)(q21.2q22)[20] |
| 11 | F × 6 | 45/Male | Not mutated | 14q; +12 | PR | FCR; NMSCT | 73 | 12+ | 47,XY,+add(12)(q13),t(14;19)(q32;13.3)[4]/46, XY[6] |
| 12 | F × 6 | 76/Female | Mutated | 13q− | PR | 8 | 30 | 46,XX,+1,der(1;15)(q10;p10)[6]/46,XX[24] | |
| 13 | F × 6 | 56/Male | Not mutated | 13q− | PR | Alkylators; other | 72 | 10+ | 47,XY,add(7)(q11.2),del(20)(q11.2q13.3), +21[18]/46,XY[2] |
Tx indicates treatment; CR, complete response; PR, partial response; F, fludarabine alone; PD, progressive disease; and NMSCT, nonmyeloablative stem cell transplantation.